Back to Journals » OncoTargets and Therapy » Volume 14

Case Report: Myeloid Sarcoma Development During Treatment for B Cell Lymphoblastic Lymphoma in a Boy with KRAS/NRAS Gene Mutations

Authors Yuan X, Yu U, Chen S, Xu H, Yi M, Jiang X, Song J, Chen X, Chen S, Lin Z, Li C, Wen F, Liu S

Received 27 September 2020

Accepted for publication 29 December 2020

Published 13 January 2021 Volume 2021:14 Pages 347—353

DOI https://doi.org/10.2147/OTT.S276912

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Nicola Silvestris


Xiuli Yuan,1,* Uet Yu,1,* Senmin Chen,1 Huanli Xu,1 Meng Yi,1 Xianping Jiang,2 Jianming Song,1 Xiaowen Chen,3 Shiyang Chen,3 Zhenhu Lin,3 Changgang Li,1 Feiqiu Wen,1 Sixi Liu1

1Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, People’s Republic of China; 2Department of Pathology, Shenzhen Children’s Hospital, Shenzhen, People’s Republic of China; 3Institute for Medical Research, Shenzhen Children’s Hospital, Shenzhen, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Sixi Liu
Department of Hematology and Oncology, Shenzhen Children’s Hospital, Yitian Road No. 7019, Futian, Shenzhen, Guangdong 518038, People’s Republic of China
Tel +86 189-3869-0206
Email tiger647@126.com

Abstract: Here, we report a rare case of a 12-year-old boy who was initially diagnosed with B cell lymphoblastic lymphoma (BLBL) and developed myeloid sarcoma (MS) eight months after chemotherapy. Next-generation sequencing (NGS) showed mutations of KRAS and NRAS genes in both the bone marrow and lymph node. He presented an abnormal karyotype of 46, XY, − 9, der (16) t (9; 16) (q13; q12), +mar. He received chemotherapy according to the South China Children’s Leukemia Group 2016 protocol. Complete remission was achieved by the 15th day post-treatment. Eight months later and immediately prior to the start of maintenance therapy, the patient developed fever, skin nodules in both upper arms, and enlargement of bilateral testes. Pathological analysis of skin and testicular biopsies suggested the diagnosis of myeloid sarcoma (MS). Again, NGS examination showed mutations of KRAS and NRAS genes. The patient underwent haploidentical hematopoietic stem cell transplantation but unfortunately did not survive. The interval of eight-month interval between the initial disease onset and MS brings into question whether MS developed as part of the initial onset of disease or as a secondary tumor in association with chemotherapy. Thus, understanding the pathogenesis of MS involving abnormalities of lymphoid progenitors may assist in the prediction of prognosis and development of novel target therapies.

Keywords: B cell lymphoblastic lymphoma, myeloid sarcoma, KRAS, NRAS, case report

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]